AI-ACCELERATED DRUG DISCOVERY
Receptor.AI to provide access to the AI drug discovery platform for Moexa
LONDON, September 10, 2024 – Receptor.AI, a next-gen TechBio company advancing a multiplatform drug discovery ecosystem, and Moexa, an IND-stage company committed to developing innovative therapies for cancer and fibrotic diseases, today announced a strategic research collaboration to develop novel small molecule therapeutics targeting challenging protein-protein interactions (PPIs) for cancer and fibrosis treatment.
Under the terms of the agreement, Receptor.AI and Moexa will combine their expertise in AI-powered drug discovery and disease biology to identify and validate novel PPI targets involved in the pathogenesis of cancer and fibrosis. Receptor.AI's proprietary Induced Proximity platform will be leveraged to design and optimize small molecule compounds against these targets. Moexa will contribute its domain knowledge and drug development capabilities to advance these compounds into clinical development.
“We are thrilled to partner with Moexa, an expert in the development of innovative therapies for cancer and fibrotic diseases,” said Dr. Alan Nafiev, CEO of Receptor.AI. “This collaboration leverages our dedicated platform and Moexa's expertise in TGF-β/SMAD biology to accelerate the discovery and development of novel therapeutics for patients suffering from related diseases.”
"Targeting PPIs represents a significant opportunity to develop transformative therapies for TGF-β signaling," said Mr. Anthony Desir, CEO of Moexa. “We believe that combining Receptor.AI's Induced Proximity Platform with our deep understanding of TGF-β/SMAD targeting will enable us to accelerate the development of novel therapeutics for patients in need."
Building on the success of ArtiDock, the world's best AI docking model, and working in collaboration with NVIDIA, Receptor.AI has made remarkable progress in integrating ArtiDock with the NVIDIA BioNeMo platform. The integration of ArtiDock with BioNeMo enhances the capabilities of both platforms, enabling the modeling of complex biological interactions and the generation of novel therapeutic candidates.
About Receptor.AI
Receptor.AI is a next-generation TechBio company advancing a multiplatform ecosystem for small molecule and peptide design. Based on Receptor.AI's proprietary AI technologies, the platforms are specialized in the design of protein proximity engagers, complex drug conjugates, and selective monospecific compounds, addressing the most challenging targets in therapeutic development.
About Moexa
Moexa is an IND-stage company dedicated to discovering, developing, and commercializing innovative therapies for TGF-β/SMAD signaling. The company's world-leading TGF-β/SMAD IP is already identified as “novel” by the US Patent Office. It focuses on addressing critical unmet medical needs, aiming to improve patient outcomes in areas with limited therapeutic options.
For Media Enquiries
